-
MedAssets Reports Fourth Quarter and Full-Year 2010 Financial Results
Thursday, February 24, 2011 - 4:08pm | 187MedAssets, Inc. (NASDAQ: MDAS) today announced results for its fourth quarter and 12-month period ended December 31, 2010, as summarized below: Net Revenue Fourth Quarter Total net revenue for the fourth quarter of 2010 increased 11.8% to $106.9 million from $95.7 million in the fourth quarter of...
-
SXC Health Solutions Reports Q4 EPS of $0.26
Thursday, February 24, 2011 - 6:09am | 56SXC Health Solutions (NASDAQ: SXCI) reports its Q4 EPS at $0.26, versus the consensus of $0.27. SXCI reports its Q4 revenue at $499.76 million, versus the consensus of $515.70 million. SXCI shares gained 1.53% to $47.22 in after-hours trading. Read more from Benzinga's Company news.
-
SXC Health Solutions Reports Q4 EPS of $0.26
Thursday, February 24, 2011 - 6:09am | 56SXC Health Solutions (NASDAQ: SXCI) reports its Q4 EPS at $0.26, versus the consensus of $0.27. SXCI reports its Q4 revenue at $499.76 million, versus the consensus of $515.70 million. SXCI shares gained 1.53% to $47.22 in after-hours trading. Read more from Benzinga's Company news.
-
Merge Healthcare Reports Q4 EPS of $0.10 vs. $0.05
Thursday, February 17, 2011 - 4:19pm | 51Merge Healthcare Incorporated (NASDAQ: MRGE) today announced financial results for the fourth quarter of 2010. Revenue grew to $46.2 million ($51.1 million on a pro forma basis) in the quarter, compared to $19.3 million in the fourth quarter of 2009 Net income available to common shareholders $...
-
Citi Has Buy Rating On Allscripts Healthcare Solutions (MDRX)
Wednesday, February 16, 2011 - 8:37am | 143Citi Investment Research has a Buy rating and a $25 price target on shares of Allscripts Healthcare Solutions (NASDAQ: MDRX). In a note to clients, Citi writes, "Allscripts, like Cerner, illustrates that the best performing HCIT businesses have a high degree of revenue and earnings visibility. It...
-
Piper Jaffray Downs MDRX To Neutral
Wednesday, February 16, 2011 - 6:01am | 50Analysts at Piper Jaffray downgrade Allscripts Healthcare Solutions Inc (NASDAQ: MDRX) from “overweight” to “neutral.” The target price for MDRX is set to $22. MDRX shares fell 1.78% to close at $21.58 yesterday. More Analyst Ratings here
-
Allscripts Reports Fourth Quarter Results
Tuesday, February 15, 2011 - 4:07pm | 204Allscripts Healthcare Solutions, Inc. (Allscripts) (NASDAQ: MDRX) today announced its financial results for the three months ended December 31, 2010. Fourth Quarter Highlights: Fourth quarter total bookings of $288.2 million, including legacy Allscripts bookings of $140.4 million and legacy...
-
Morgan Stanley Initiates MDAS With Equal Weight
Tuesday, February 15, 2011 - 6:34am | 43Analytss at Morgan Stanley initiate coverage of MedAssets Inc (NASDAQ: MDAS) with an “equal weight” rating. MDAS shares gained 1.81% to close at $20.84 yesterday. More Analyst Ratings here
-
Options Brief: Allscripts Healthcare Solutions (MDRX)
Monday, February 14, 2011 - 10:53am | 87Shares of Allscripts Healthcare Solutions (NASDAQ: MDRX) are lower on the session by 0.05%, trading at $22.04. Overall put volume is now running at 11.60x the daily average, with 33% of all puts traded being purchases on the offer. 1,044 contracts have traded on the session so far. Allscripts...
-
Merger Arbitrage Mondays – February 14, 2011
Monday, February 14, 2011 - 5:24am | 4875Merger activity increased last week with seven new deals announced and five deals closing. You can find all the deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: Total Number of Deals Closed in 2011 19 Total Number of Pending...
-
MGT Announces Resignation of CEO Allan Rowley
Thursday, February 10, 2011 - 2:48pm | 72MGT Capital Investments, Inc. (NYSE: MGT) announced today that Allan Rowley has resigned as Chief Executive Officer and as a Director of MGT. Richard Cohen, Esq. has joined the Company as an independent Director to replace Mr. Rowley. In addition, Robert Ladd, presently a Director of the Company...
-
Cerner Reports Strong 4Q, JP Morgan Raises PT To $115
Wednesday, February 9, 2011 - 9:23am | 148JP Morgan has published a research report on Cerner Corporation (NASDAQ: CERN) after the company reported strong 4Q results. In the report, JP Morgan writes "4Q bookings of $626M were well ahead of our $510M forecast and company guidance of $490-530M. The number of contracts signed in excess of $5M...
-
Cerner Reports Strong 4Q, JP Morgan Raises PT To $115
Wednesday, February 9, 2011 - 9:23am | 148JP Morgan has published a research report on Cerner Corporation (NASDAQ: CERN) after the company reported strong 4Q results. In the report, JP Morgan writes "4Q bookings of $626M were well ahead of our $510M forecast and company guidance of $490-530M. The number of contracts signed in excess of $5M...
-
JP Morgan Raises PT On Cerner Corporation To $116
Wednesday, February 9, 2011 - 8:39am | 27JP Morgan has raised the price target on Cerner Corporation (NASDAQ: CERN) from $110 to $116 and maintains its Overweight rating.
-
Morgan Keegan Raises PT On Cerner Corporation To $109
Wednesday, February 9, 2011 - 8:07am | 27Morgan Keegan has raised the price target on Cerner Corporation (NASDAQ: CERN) from $106 to $109 and maintains its Outperform rating.